First participant joins groundbreaking CLARITY trial by Aclarion for Ortho Spine News

Aclarion, a healthcare technology company focused on improving spine care, has enrolled its first patient in the CLARITY trial at the Texas Back Institute, known for its contributions to spine technology and patient care. The CLARITY trial aims to showcase Nociscan’s ability to enhance surgical outcomes for chronic low back pain, with the goal of setting a new standard in identifying the sources of this prevalent issue using MR Spectroscopy (MRS) and Augmented Intelligence (AI). The Company anticipates releasing internal interim results of the trial in the second quarter of 2026.

The primary investigator for the CLARITY trial, Dr. Alexander Satin, expressed enthusiasm about Texas Back Institute’s involvement in advancing spine care through clinical research. The trial will provide valuable insights into patient-specific pain biomarker data and its correlation with surgical results, utilizing the innovative Nociscan platform. The study will involve 300 patients across various high-volume medical centers in the US, all receiving a Nociscan assessment before surgery. The trial will gauge the change in back pain at 12 months post-surgery compared to baseline, with additional secondary measures captured.

Chronic low back pain is a widespread issue affecting millions of individuals globally. Aclarion’s Nociscan solution, backed by evidence, offers a Software as a Service (SaaS) platform that can help physicians differentiate between painful and nonpainful discs in the lumbar spine without invasive procedures. By quantifying chemical biomarkers associated with disc pain, Nociscan has the potential to enhance surgical outcomes and optimize patient care.

The CLARITY trial is another step forward in addressing the complexities of chronic low back pain by leveraging cutting-edge technology and medical expertise. Collaborating with esteemed medical institutions like Johns Hopkins Medicine, Keck Medicine at USC, and the University of Miami Health System, Aclarion is poised to make a significant impact on the field of spine care. Nociscan’s ability to provide critical insights into the origin of low back pain offers physicians a valuable tool to tailor treatment strategies effectively.

Aclarion’s commitment to innovation and excellence in healthcare is evident through its development of Nociscan and participation in groundbreaking trials like CLARITY. By harnessing the power of MRS, proprietary algorithms, and biomarkers, the Company is revolutionizing the way chronic low back pain is diagnosed and treated. With a focus on optimizing clinical treatments and enhancing patient outcomes, Aclarion is at the forefront of driving advancements in spine care technology.

In conclusion, the enrollment of the first patient in the CLARITY trial signifies a significant milestone in Aclarion’s mission to improve spine care and address the challenges associated with chronic low back pain. Through collaboration with leading medical institutions and the development of innovative solutions like Nociscan, Aclarion is paving the way for a future where spine care is more precise, effective, and patient-centered.